VMT Scientific Inc. Announces Funding

Published: Dec 07, 2005

LAS VEGAS, Dec. 7 /PRNewswire-FirstCall/ -- VMT Scientific Inc. is proud to announce that it has secured funding that will empower us to remain focused with respect in achieving proper efficacy testing of the VasCir(TM) device. After assessing our Phase II financial needs and developing a cost analysis, we are confident that these funds will enable us to execute and achieve our objectives as defined for Phase II.

As always, we extend an invitation to view our website http://www.vmtf.org so as to have a clear understanding of our focus and technology.

This Press Release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in the forward- looking statements, particularly those risks and uncertainties inherent in the process of developing, manufacturing and distributing medical products and Clinical trials. Factors that may cause such a difference include risks related to VMT Scientific Inc.'s limited operating history, risks associated with completing development and obtaining FDA medical approvals, successful patent protection and prosecution, successful sale of licensed technology nationally or internationally. VMT Scientific technology will not meet with market acceptance, the risk of future warranty and product liability claims, the uncertainty of VMT Scientific Inc.'s future access to capital to sustain operations, achieve profitability or continue as a going concern, the failure by VMT Scientific Inc.'s to secure and maintain relationships with suppliers, manufacturers and other third parties, reliance on key employees, and dependence on intellectual property. These forward-looking statements are based on information and management's expectations as of the date hereof. Future results may differ materially from our current expectations.

VMT Scientific Inc.

CONTACT: Catherine S. Ratelle, Director of Operations, VMT Scientific,Inc., +1-702-990-3477, docs@vmtf.org

Back to news